Home | About Jay Hochman -Pediatric Gastroenterology Blog | Archives
July 3, 2015 7:00 am
A recent retrospective single-center study (Papmichael K et al. Clin Gastroenterol Hepatol 2015; 13: 1103-10) of 100 patients with Crohn’s disease examined what happens to patients who discontinued infliximab therapy upon clinical remission. The study used a medical database in Belgium. The authors defined sustained clinical remission (SCR) as “maintenance of disease remission, without escalation in medical therapy or CD-related surgeries, until the end of the follow-up period, which was a median period of approximately 10 years.” 84 patients continued on immunomodulator therapy.
Key findings:
Limitations: SCR was based on physician global assessment which may underestimate relapse rates and endoscopic data at the time of infliximab discontinuation was available in only a small subgroup.
Bottomline: In this small study, half of the patients did well clinically for a long time after stopping infliximab (most remained on immunomodulator therapy). However, given the insidious nature of Crohn’s disease, careful monitoring before and after stopping infliximab is worthwhile. In addition, other studies have demonstrated higher relapse rates.
Related blog posts:
Posted by gutsandgrowth
Categories: inflammatory bowel disease, Pediatric Gastroenterology Intestinal Disorder
Tags: Crohn's disease, infliximab discontinuation, mucosal healing, withdrawal
Mobile Site | Full Site
Get a free blog at WordPress.com Theme: WordPress Mobile Edition by Alex King.
[…] Stopping Infliximab -What Happens Next? | gutsandgrowth […]
By High Risk of Relapse in Younger Patients after anti-TNF Therapy Withdrawal | gutsandgrowth on February 29, 2016 at 7:02 am
[…] Stopping Infliximab –What Happens Next? | gutsandgrowth […]
By When Remicade is Stopped and Restarted (More Data) | gutsandgrowth on January 29, 2017 at 9:01 am